NCT04467515 - A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment

Interventions

DRUG

CAM-H2

All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.

Trial Locations (12)

10021

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

20057

Georgetown University Medical Center, Washington D.C.

21061

Advanced Molecular Imaging & Therapy, Glen Burnie

21287

Johns Hopkins Hospital, Baltimore

52242

University of Iowa, Iowa City

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine in St. Louis, St Louis

91010

City of Hope, Duarte

94305

Stanford University Medical Center, Stanford

Unknown

Princess Margaret Hospital, Toronto

Hospital Notre Dame du CHUM, Montreal

McGill University Faculty of Medicine - Royal Victoria Hospital, Montreal